EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Update and Practical Recommendations for the Use of Medical Treatment of Cushing Syndrome

Marta Araujo-Castro iD, Cristina Lamas iD, Elisabeth Nowak iD, John Newell-Price iD, Martin Reincke iD, Frederic Castinetti iD

Endocrine Reviews · 13.05.2026 · 47 (3) · 301-328

DOI: 10.1210/endrev/bnaf042 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Endocrine Reviews, online erschienen am 05.01.2026. Verfasst von Marta Araujo-Castro und 5 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology & Nutrition Department, Ramón y Cajal Hospital, 28034 Madrid, Spain. Hauptthemen laut MEDLINE: Cushing Syndrome, Steroid Synthesis Inhibitors. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 241 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, European Union.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Medical treatment of hypercortisolism may be necessary for a high proportion of patients with Cushing syndrome (CS), including those who are not candidates for curative surgery. It may also be used in the presurgical period when hypercortisolism is severe, as long-term treatment following surgical failure or recurrence after surgery, or while waiting for the effects of pituitary radiation in Cushing disease. Currently available medical treatments include adrenal steroidogenesis inhibitors that block cortisol secretion (ketoconazole, levoketoconazole, metyrapone, osilodrostat, mitotane, and etomidate), drugs that modulate pituitary ACTH secretion (pasireotide and cabergoline), and drugs that block peripheral glucocorticoid receptors (mifepristone). In addition, there are other medical treatments in development that target pituitary signaling pathways, ACTH or its adrenal receptor, or the conversion of cortisol from cortisone by 11ßHSD1. Steroidogenesis inhibitors can be administered using either a titration or a block-and-replace approach. Titration requires adjusting the daily drug dose with the aim of normalizing circulating cortisol levels, whereas the block-and-replace strategy uses higher drug doses to fully suppress endogenous cortisol production, followed by glucocorticoid supplementation. In this review, we summarize the main indications for medical treatment in CS, the mechanism of drug action, efficacy, recommended doses, and safety of the currently available drugs, as well as potential future treatments. We also discuss titration and block-and-replace approaches for control of hypercortisolism and provide recommendations for the use and monitoring of medical treatment in CS, including patients with endogenous hypercortisolism in special situations such as pregnancy, cyclic CS, and mild autonomous cortisol secretion.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cushing SyndromeSteroid Synthesis InhibitorsHumansMetyraponePractice Guidelines as Topic

Stichwörter der Autor:innen

Cushing syndromeketoconazolelevoketoconazolemetyraponeosilodrostat

Substanzen

Steroid Synthesis InhibitorsMetyrapone

Autor:innen und Institutionen

  • Endocrinology & Nutrition Department, Ramón y Cajal Hospital, 28034 Madrid, Spain.
  • Instituto de Investigación Biomédica Ramón y Cajal (IRYCIS), 28034 Madrid, Spain.
  • Endocrinology & Nutrition Department, Complejo Hospitalario Universitario de Albacete, 02006 Albacete, Spain.
  • Department of Medicine IV, LMU University Hospital, LMU Munich, 81377 Munich, Germany.
  • School of Medicine and Population Health, University of Sheffield, Sheffield S10 T2N, UK.
  • Aix Marseille Univ, INSERM U1251, Marseille Medical Genetics, 13005 Marseille, France.

ORCID-Profile: Marta Araujo-Castro, Cristina Lamas, Elisabeth Nowak, John Newell-Price, Martin Reincke, Frederic Castinetti

Förderung

  • Instituto de Salud Carlos III
  • European Union

Zitieren

APA

Araujo-Castro, M., Lamas, C., Nowak, E., Newell-Price, J., Reincke, M., & Castinetti, F. (2026). Update and Practical Recommendations for the Use of Medical Treatment of Cushing Syndrome. Endocrine Reviews, 47(3), 301-328. https://doi.org/10.1210/endrev/bnaf042

Vancouver

Araujo-Castro M, Lamas C, Nowak E, Newell-Price J, Reincke M, Castinetti F. Update and Practical Recommendations for the Use of Medical Treatment of Cushing Syndrome. Endocrine Reviews. 2026;47(3):301-328. doi:10.1210/endrev/bnaf042

BibTeX
@article{AraujoCastro2026,
  author = {Araujo-Castro, Marta and Lamas, Cristina and Nowak, Elisabeth and Newell-Price, John and Reincke, Martin and Castinetti, Frederic},
  title = {Update and Practical Recommendations for the Use of Medical Treatment of Cushing Syndrome},
  journal = {Endocrine Reviews},
  year = {2026},
  volume = {47},
  number = {3},
  pages = {301--328},
  doi = {10.1210/endrev/bnaf042}
}
Kostenlos starten →